OncoMatch/Clinical Trials/NCT06137144
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Official title: A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies
Is NCT06137144 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies multiple treatments including AZD3470 and Pembrolizumab for lymphoma.
Treatment: AZD3470 · Pembrolizumab — This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma
Biomarker criteria
Required: MTAP deficiency
Disease stage
Required: Stage III, IV
Demographics
Prior therapy
Must have received: systemic therapy for cHL
Previous treatment with at least 2 prior lines of therapy for the treatment of cHL (including at least 2 cycles of BV and anti-PD1) and have documented r/r active disease requiring treatment.
Must have received: combination chemotherapy for cHL (A-AVD, N-AVD, AVD, ABVD) — first-line induction
previously received at least 4 cycles of SoC combination therapy with A-AVD, N-AVD, AVD, or ABVD (based on regional SOC, per investigator) as finite first-line induction therapy, and achieved at least a PR post-induction therapy.
Must have received: systemic therapy for PTCL
Participants must have received at least 1 prior line of therapy for the treatment of PTCL and have exhausted all available therapies with demonstrated clinical benefit. Participants with ALCL must have received prior BV treatment.
Must have received: systemic therapy for cHL
Participant must have received at least 1 prior line of therapy for the treatment of cHL and have documented r/r active disease requiring treatment.
Cannot have received: MAT2A inhibitor
Received ... MAT2A or PRMT5 inhibitor
Cannot have received: PRMT5 inhibitor
Received ... MAT2A or PRMT5 inhibitor
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
Liver function
Adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Duarte, California
- Research Site · Miami, Florida
- Research Site · Atlanta, Georgia
- Research Site · Boston, Massachusetts
- Research Site · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06137144 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MAT2A inhibitor, PRMT5 inhibitor disqualifies patients from enrollment.
Does this trial require MTAP?
Yes, MTAP deficiency is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages